ALAMEDA, Calif. , July 31, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the second quarter ended June 30, 2019 , on
ALAMEDA, Calif. , July 24, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, molecular diagnostic tests for the early detection and management of cancer, today announced the appointment of Melinda Griffith to its Board of Directors.
ALAMEDA, Calif. , June 26, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today provided a mid-year update and announced that the Company will require additional time to complete its ongoing CLIA
ALAMEDA, Calif. , June 11, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of lung cancer, today announced that the company will be added to the Russell 2000®, Russell 3000® and Russell Microcap Indexes, effective
Appoints diagnostic industry veteran and current Board member Ronald Andrews, Jr. as Chief Executive Officer Outgoing CEO William Annett to serve as an advisor to the Company Company to host conference call and webcast today, June 6 , at 8:30am EDT ALAMEDA, Calif.
Company presentation scheduled for Wednesday, June 5 at 10:45am EDT ALAMEDA, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced that Chief Executive Officer William
Padma Sundar Appointed Senior Vice President, Marketing and Market Access Dr. Kim Dickinson Appointed Vice President, Clinical Operations ALAMEDA, Calif. , May 29, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection
Results were achieved using blood gene expression biomarkers alone and without the use of clinical parameters Company remains on-track to make DetermaVu™ commercially available in 2H 2019 ALAMEDA, Calif. , May 21, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of
Completes successful Analytical Validation study and initiates CLIA Validation study On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif. , May 14, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of
Company to host conference call and webcast at 4:30pm ET ALAMEDA, Calif. , May 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results
On track for commercial availability of DetermaVu™ in 2H 2019 Conference Call Today at 4:30 PM EDT ALAMEDA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of lung cancer, today reported
Poster presentation and discussion to detail compelling results from R&D Validation study of the Company’s DetermaVu™ liquid biopsy test for the early detection of lung cancer ALAMEDA, Calif. , April 01, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel,
ALAMEDA, Calif. , March 25, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of cancer, announced today that it will release its financial and operating results for the fourth quarter and year ended December 31,
ALAMEDA, Calif. , March 06, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced that William Annett , CEO of OncoCyte Corporation , will be presenting at the Cowen and Company 39 th Annual
Company remains on-track for commercial availability of DetermaVu™ Lung in 2H 2019 ALAMEDA, Calif. , March 04, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced the initiation of the
ALAMEDA, Calif. , Feb. 12, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the closing of an underwritten public offering.
ALAMEDA, Calif. , Feb. 08, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced the pricing of an underwritten public offering of 9,333,334 shares of its common
ALAMEDA, Calif. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) (“OncoCyte”), a developer of novel, non-invasive liquid biopsy tests for the early detection of cancer, today announced that it intends to offer and sell shares of its common stock in an underwritten
Results show 90% sensitivity and 75% specificity, demonstrating best-in-class performance On track for commercial availability of DetermaVu™ Lung in 2H 2019 Results suggest the potential to address a U.S. market opportunity of $4.7 billion Unique immune system interrogation approach may have
Conference call scheduled for Tuesday, January 29, 2019 at 8:30am ET ALAMEDA, Calif , Jan. 28, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today scheduled an announcement and conference call to
FREMONT, Calif. , Jan. 24, 2019 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today
30M U.S. adults suffer from diabetes and 93M from obesity, with associated medical costs of over $300B annually, necessitating an urgent need for novel treatments AgeX-BAT1 for Type II diabetes and obesity aims to return brown adipose tissue, also known as “brown” or “good” fat, back to levels
Ion GeneStudio™ S5 Demonstrates Generation of Consistent and Reproducible Results in Lung Cancer Studies ALAMEDA, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE American: OCX) , a developer of novel, non-invasive tests for the early detection of cancer, today announced its
ALAMEDA, Calif. --(BUSINESS WIRE)--Jan. 2, 2019-- AgeX Therapeutics , Inc. (NYSE American: AGE), a biotechnology company focused on developing and commercializing innovative therapeutics for human aging, today announced that it will present at Biotech Showcase , to be held January 7-9, 2019 in San
